Budget impact analysis of transcatheter aortic valve replacement in low, intermediate, and high-risk patients with severe aortic stenosis in Saudi Arabia

References

• Otto CM, Prendergast B. Aortic-Valve stenosis — from patients at risk to severe valve obstruction. Massachusetts Med Soc. 2014;371:744–756. https://doi.org/10.1056/NEJMra1313875.
   Google Scholar
• Go AS, Mozaffarian D, Roger VL. et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245.,
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams RJ, Brown TM. et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948–954.,
   PubMed Web of Science ®Google Scholar
• Varadarajan P, Kapoor N, Bansal RC, et al. Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg. 2006;82(6):2111–2115.
   PubMed Web of Science ®Google Scholar
• Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129(23):2440–2492.,
   PubMed Web of Science ®Google Scholar
• Coylewright M, Palmer R, O’Neill ES, et al. Patient-defined goals for the treatment of severe aortic stenosis: a qualitative analysis. Health Expect. 2016;19(5):1036–1043.
   PubMed Web of Science ®Google Scholar
• Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. The Lancet. 2006;368(9540):1005–1011.
   PubMed Web of Science ®Google Scholar
• De Sciscio P, Brubert J, De Sciscio M, et al. Quantifying the shift toward transcatheter aortic valve replacement in low-risk patients: a meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10(6):e003287.
   PubMed Web of Science ®Google Scholar
• Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the euro heart survey on valvular heart disease. Eur Heart J. 2003;24(13):1231–1243.
   PubMed Web of Science ®Google Scholar
• Alatawi FO, Abuelatta RA, AlAhmedi AB, et al. Clinical outcomes with transcatheter aortic valve implantation at a single cardiac center in Saudi Arabia. Ann Saudi Med. 2018;38(3):167–173.
   PubMed Web of Science ®Google Scholar
• Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187–2198.
   PubMed Web of Science ®Google Scholar
• Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366(18):1686–1695.
   PubMed Web of Science ®Google Scholar
• Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385(9986):2477–2484.
   PubMed Web of Science ®Google Scholar
• Reynolds MR, Magnuson EA, Wang K, et al. Health-Related quality of life after transcatheter or surgical aortic valve replacement in High-Risk patients with severe aortic stenosis: results from the PARTNER (placement of AoRTic TraNscathetER valve) trial (cohort a). J Am Coll Cardiol. 2012;60(6):548–558.
   PubMed Web of Science ®Google Scholar
• Arnold SV, Reynolds MR, Wang K, et al. Health status after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis at increased surgical risk: results from the CoreValve US pivotal trial. JACC Cardiovasc Interv. 2015;8(9):1207–1217.,
   PubMed Web of Science ®Google Scholar
• EuroPCR. 2015. The SAPIEN 3 Trials – One Year Outcomes | Radcliffe Cardiology [Internet]; [cited 2021 Sep 15]. Available from: https://www.radcliffecardiology.com/video-index/europcr-2015-sapien-3-trials-one-year-outcomes.
   Google Scholar
• Herrmann HC, Thourani VH, Kodali SK, et al. One-Year clinical outcomes with SAPIEN 3 transcatheter aortic valve replacement in High-Risk and inoperable patients with severe aortic stenosis. Circulation. 2016;134(2):130–140.
   PubMed Web of Science ®Google Scholar
• Kodali S, Thourani VH, White J, et al. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur Heart J. 2016;37(28):2252–2262.
   PubMed Web of Science ®Google Scholar
• Webb J, Gerosa G, Lefèvre T, et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol. 2014;64(21):2235–2243.
   PubMed Web of Science ®Google Scholar
• Romano M, Frank D, Cocchieri R, et al. Transaortic transcatheter aortic valve implantation using SAPIEN XT or SAPIEN 3 valves in the ROUTE registry†. Interact Cardiovasc Thorac Surg. 2017;25(5):757–764.
   PubMed Web of Science ®Google Scholar
• Cocchieri R, Petzina R, Romano M, et al. Outcomes after transaortic transcatheter aortic valve implantation: long-term findings from the European ROUTE†. Eur J Cardiothorac Surg. 2019;55(4):737–743.
   PubMed Web of Science ®Google Scholar
• Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016;387(10034):2218–2225.
   PubMed Web of Science ®Google Scholar
• Kodali S. SAPIEN 3 transcatheter aortic valve replacement compared with surgery in intermediate-risk patients: a propensity-matched analysis of 5-year outcomes [Internet]. TCTMD.com. 2020; [cited 2021 Sep 15]. Available from: https://www.tctmd.com/slide/sapien-3-transcatheter-aortic-valve-replacement-compared-surgery-intermediate-risk-patients-0.
   Google Scholar
• Tuzcu EM. Real world outcomes of TAVR with the SAPIEN 3 valve in intermediate risk patients: comparison of data form the TVT registry with PARTNER S3 studies. Paris, France; 2018.
   Google Scholar
• Edwards Lifesciences. A prospective, randomized, controlled, multi-center study to establish the safety and effectiveness of the SAPIEN 3 Transcatheter heart valve in low risk patients who have severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement [Internet]. clinicaltrials.gov. 2021; [cited 2021 Sep 13]. Report No.: NCT02675114. Available from: https://clinicaltrials.gov/ct2/show/NCT02675114.
   Google Scholar
• Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve replacement with a Balloon-Expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695–1705.
   PubMed Web of Science ®Google Scholar
• Waksman R, Rogers T, Torguson R, et al. Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis. J Am Coll Cardiol. 2018;72(18):2095–2105.
   PubMed Web of Science ®Google Scholar
• Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol. 2021;77(9):1149–1161.,
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices-budget impact analysis. Value Health. 2007;10(5):336–347.
   PubMed Web of Science ®Google Scholar
• Orlewska E, Gulácsi L. Budget-impact analyses: a critical review of published studies. Pharmacoeconomics. 2009;27(10):807–827.
   PubMed Web of Science ®Google Scholar
• van de Vooren K, Duranti S, Curto A, et al. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy. 2014;12(1):33–40.
   PubMedGoogle Scholar
• Al-Omar HA, Aljuffali IA, Solà-Morales O. Value drivers for pharmaceutical products in health technology assessment (HTA) in Saudi Arabia: results from a capacity building, multi-stakeholder workshop. Saudi Pharm J. 2021;29(9):946–954.
   PubMed Web of Science ®Google Scholar
• Al-Omar HA, Attuwaijri AA, Aljuffali IA. Pharmaceutical companies’ views on a health technology assessment (HTA) entity in Saudi Arabia. Saudi Pharm J. 2020;28(6):662–668.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Health Observatory, Life tables [Internet]. WHO. World Health Organization; [cited 2021 Sep 21]. Available from: https://apps.who.int/gho/data/view.main.61440?lang=en.
   Google Scholar
• Chello C, Lusini M, Nenna A, et al. Deep sternal wound infection (DSWI) and mediastinitis after cardiac surgery: current approaches and future trends in prevention and management. Surg Technol Int. 2020;36:212–216.
   PubMedGoogle Scholar
• Hawkins RB, Mehaffey JH, Charles EJ, et al. Cost-effectiveness of negative pressure incision management system in cardiac surgery. J Surg Res. 2019;240:227–235.
   PubMed Web of Science ®Google Scholar
• Schiraldi L, Jabbour G, Centofanti P, et al. Deep sternal wound infections: evidence for prevention, treatment, and reconstructive surgery. Arch Plast Surg. 2019;46(4):291–302.
   PubMedGoogle Scholar
• Tegnell A, Arén C, Ohman L. Coagulase-negative staphylococci and sternal infections after cardiac operation. Ann Thorac Surg. 2000;69(4):1104–1109.
   PubMed Web of Science ®Google Scholar
• Ridderstolpe L, Gill H, Granfeldt H, et al. Superficial and deep sternal wound complications: incidence, risk factors and mortality. Eur J Cardiothorac Surg. 2001;20(6):1168–1175.
   PubMed Web of Science ®Google Scholar
• Sjögren J, Malmsjö M, Gustafsson R, et al. Poststernotomy mediastinitis: a review of conventional surgical treatments, vacuum-assisted closure therapy and presentation of the lund University Hospital mediastinitis algorithm. Eur J Cardiothorac Surg. 2006;30(6):898–905.
   PubMed Web of Science ®Google Scholar
• Heilmann C, Stahl R, Schneider C, et al. Wound complications after median sternotomy: a single-centre study. Interact Cardiovasc Thorac Surg. 2013;16(5):643–648.
   PubMed Web of Science ®Google Scholar
• Shehada S-E, Wendt D, Peters D, et al. Infections after transcatheter versus surgical aortic valve replacement: mid-term results of 200 consecutive patients. J Thorac Dis. 2018;10(7):4342–4352.
   PubMed Web of Science ®Google Scholar
• Tirado-Conte G, Freitas-Ferraz AB, Nombela-Franco L, et al. Incidence, causes, and impact of in-Hospital infections after transcatheter aortic valve implantation. Am J Cardiol. 2016;118(3):403–409.
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Mancone M, et al. Early, intermediate and late infectious complications after transcatheter or surgical aortic-valve replacement: a prospective cohort study. Clin Microbiol Infect. 2014;20(8):758–763.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Chakravarty T, Jilaihawi H, et al. Complete percutaneous approach for arterial access in transfemoral transcatheter aortic valve replacement: a comparison with surgical cut-down and closure. Catheter Cardiovasc Interv. 2014;84(2):293–300.
   PubMed Web of Science ®Google Scholar
• Wu Y-C, Zhang J-F, Shen W-F, et al. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis: a meta analysis. Chin Med J. 2013;126(6):1171–1177.
   PubMed Web of Science ®Google Scholar
• Shehada S-E, Elhmidi Y, Öztürk Ö, et al. Transcatheter versus surgical aortic valve replacement after previous cardiac surgery: a systematic review and meta-analysis. Cardiol Res Pract. 2018;2018:1–11.
   Web of Science ®Google Scholar
• Klein H, Boleckova J. Resource utilization and procedure-related costs associated with transfemoral transcatheter aortic valve replacement. J Med Econ. 2017;20(6):640–645.
   PubMed Web of Science ®Google Scholar
• Tam DY, Azizi PM, Fremes SE, et al. The cost-effectiveness of transcatheter aortic valve replacement in low surgical risk patients with severe aortic stenosis. Eur Heart J Qual Care Clin Outcomes. 2020;2020:qcaa058.
   Google Scholar
• Doble B, Blackhouse G, Goeree R, et al. Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis: a Canadian perspective. J Thorac Cardiovasc Surg. 2013;146(1):52–60.e3.
   PubMed Web of Science ®Google Scholar
• Baron SJ, Wang K, House JA. et al. Cost-Effectiveness of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at intermediate risk. Circulation. 2019;139(7):877–888.
   PubMed Web of Science ®Google Scholar
• Hersi AS, Osenenko KM, Kherraf SA, et al. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia. Ann Saudi Med. 2019;39(4):265–278.
   PubMed Web of Science ®Google Scholar
• Tarride J-E, Luong T, Goodall G, et al. A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients. Clinicoecon Outcomes Res. 2019;11:477–486.
   PubMed Web of Science ®Google Scholar
• Zhou J, Liew D, Duffy SJ, et al. Cost-effectiveness of transcatheter aortic valve implantation compared to surgical aortic valve replacement in the intermediate surgical risk population. Int J Cardiol. 2019;294:17–22.
   PubMed Web of Science ®Google Scholar
• Shah KK, Elder D, Nguyen MTH, et al. Transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement for aortic stenosis (SAVR): a cost-comparison study. Heart Lung Circ. 2021;2021:S1443-9506(21)00550-3.
   Google Scholar
• Health Information and Quality Authority. Health Technology Assessment of transcatheter aortic valve implantation (TAVI) in patients with severe symptomatic aortic stenosis at low and intermediate risk of surgical complications [Internet]. Health Information and Quality Authority; 2019; [cited 2021 Sep 23]. Available from: https://www.hiqa.ie/sites/default/files/2019-12/TAVI_HTA.pdf.
   Google Scholar
• Norwegian Institute of Public Health. Transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis and low surgical risk and across surgical risk groups [Internet]. Norwegian Institute of Public Health. 2021; [cited 2021 Sep 23]. Available from: https://www.fhi.no/en/publ/2021/TAVI-vs-SAVR-for-patients-with-severe-aortic-stenosis-and-low-surgical-risk-and-across-surgical-risk-groups/.
   Google Scholar
• Gilard M, Eltchaninoff H, Iung B, et al. Cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation procedure compared with surgery in patients with severe aortic stenosis at low risk of surgical mortality in France. Value in Health. 2021;22(4):289–296. https://www.valueinhealthjournal.com/article/S1098-3015(21)01786-1/fulltext.
   Google Scholar
• Al-Senani F, Al-Johani M, Salawati M, et al. A national economic and clinical model for ischemic stroke care development in Saudi Arabia: a call for change. Int J Stroke. 2019;14(8):835–842.
   PubMed Web of Science ®Google Scholar
• Alharthy A, Karakitsos D. King saud medical city intensive care unit: a critical and cost-focused appraisal. Saudi Crit Care J. 2019;3(1):19–23.
   Google Scholar
• Altowaijri A, Alshehri N, Balkhi B, et al. PCV50 economic burden of major cardiovascular diseases and ischemic stroke in Saudi Arabia: a cost of illness study. Value in Health. 2020;23:S495–S496.
   PubMed Web of Science ®Google Scholar
• Johnston KM, Osenenko KM, Qatami L, et al. Health care resource utilization and costs in individuals with atrial fibrillation in United Arab Emirates and kingdom of Saudi Arabia: a retrospective cohort study. Int J Int Med. 2015;4:17–25.
   Google Scholar
• Independent Hospital Pricing Authority. Development of the admitted care classifications: Public Consultation [Internet]. Independent Hospital Pricing Authority; 2021; [cited 2021 Sep 23]. Available from: https://www.ihpa.gov.au/sites/default/files/development_of_the_admitted_care_classifications_pdf_0.pdf.
   Google Scholar
• Rai D, Tahir MW, Chowdhury M, et al. Transcatheter aortic valve replacement same-day discharge for selected patients: a case series. Eur Heart J Case Rep. 2021;5(2):ytaa556.
   PubMedGoogle Scholar
• Butala N. Economics of minimalist TAVR: the 3M TAVR economic study. Boston, USA; 2021.
   Google Scholar
• Haute Autorité de Santé. EDWARDS SAPIEN 3, bioprothèse valvulaire aortique implantée par voie transfémorale (système COMMANDER) [Internet]. Commission Nationale d’Evaluation des Dispositifs Medicaux et des Technologies de Sante; 2021; [cited 2021 May 2]. Available from: https://www.has-sante.fr/upload/docs/evamed/CNEDIMTS-6294_EDWARDS_SAPIEN3_16_03_2021_(6294)_avis.pdf.
   Google Scholar